文献速递核素与放射性配体治疗放射性药物与辐射防护

肾单位水平剂量学揭示161Tb与177Lu-DOTATATE在小鼠肾脏中吸收剂量异质性增加尽管药代动力学相似

Nephron-Level Dosimetry Reveals Increased Absorbed Dose Heterogeneity of 161Tb- Versus 177Lu-DOTATATE in Murine Kidneys Despite Similar Pharmacokinetics.
PubMed 文献 · J Nucl Med · 2026-08-03

本研究在C57BL6/Jjr小鼠中比较[161Tb]Tb-DOTATATE与[177Lu]Lu-DOTATATE的肾脏剂量学,采用简化全肾剂量学与基于多肾单位计算模型的肾单位亚结构水平剂量学。两种药物药代动力学相似,但161Tb在肾单位亚结构间的吸收剂量异质性显著高于177Lu,简化全肾剂量学低估近端小管吸收剂量。

要点

  • 161Tb与177Lu-DOTATATE药代动力学相似,但161Tb肾单位亚结构吸收剂量异质性显著更高。
  • 近端小管吸收剂量平均比肾小球高71%(161Tb)和28%(177Lu)。
  • 简化全肾剂量学低估近端小管吸收剂量达35%(161Tb)和24%(177Lu)。

核心结论

  • 肾单位亚结构水平剂量学揭示两种放射性药物均存在显著吸收剂量异质性,而简化全器官剂量学未考虑此异质性。

研究设计与样本

  • 研究在C57BL6/Jjr小鼠中评估[161Tb]Tb-DOTATATE与[177Lu]Lu-DOTATATE的肾脏剂量学,采用两种剂量学框架。
  • 在注射后5个时间点(15分钟、1小时、4或4.5小时、24小时和72小时)评估详细生物分布数据。
  • 通过全肾γ计数和肾脏切片定量数字放射自显影测定不同肾单位亚结构的活性。
  • 将假设均匀吸收剂量分布的简化剂量学与基于多肾单位计算模型的肾单位亚结构水平剂量学进行比较。

主要发现

  • 两种放射性药物均表现出相似的药代动力学,肾脏清除迅速,注射后15分钟摄取达峰。
  • 161Tb在肾单位亚结构间的吸收剂量异质性显著高于177Lu。
  • 近端小管吸收剂量平均比肾小球高71%(161Tb)和28%(177Lu)。
  • 简化全肾剂量学低估近端小管吸收剂量达35%(161Tb)和24%(177Lu),并高估或低估肾小球吸收剂量,尤其对161Tb。
  • 两种放射性药物的最高吸收剂量均见于近髓肾单位,反映其独特形态。

临床怎么用

  • 小尺度剂量学可识别可能的剂量限制性肾单位亚结构,为未来肾保护策略提供信息并改进新型放射性配体的转化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The β--emitter 161Tb is emerging as a promising radionuclide for radiopharmaceutical therapy because of its increased yield of low-energy electrons compared with 177Lu. This results in an increased localized absorbed dose, potentially influencing nephrotoxicity with 161Tb. Because of the excretion and reabsorption in specific kidney tissues of radiopharmaceuticals, substructure-level dosimetry is of interest for improving understanding of radiation-induced kidney damage in radiopharmaceutical therapy. This study investigated the renal dosimetry of [161Tb]Tb-DOTATATE and [177Lu]Lu-DOTATATE in C57BL6/Jjr mice using 2 different dosimetry frameworks. Methods: Detailed biodistribution data were assessed at 5 time points postinjection (15 min, 1 h, 4 or 4.5 h, 24 h, and 72 h). The activity in different nephron substructures was determined by γ-counting of the entire kidney and quantitative digital autoradiography acquisition of kidney sections. Tissue-level activity was distributed between nephron substructures. Simplistic dosimetry assuming uniform absorbed dose distribution was compared with nephron-substructure-level dosimetry based on a multinephron computational model. Results: Both radiopharmaceuticals exhibited similar pharmacokinetics, with rapid renal clearance and peak uptake at 15 min postinjection. 161Tb resulted in a significantly increased absorbed dose heterogeneity across nephron substructures compared with 177Lu. Absorbed doses to proximal tubules were on average 71% higher than to glomeruli for 161Tb and 28% higher for 177Lu. Simplistic whole-kidney dosimetry underestimated proximal tubule absorbed doses by up to 35% for 161Tb and 24% for 177Lu and over- or underestimated glomerular absorbed doses, particularly for 161Tb. The highest absorbed doses were observed in the juxtamedullary nephrons for both radionuclides, reflecting their distinct morphology. Conclusion: Nephron-substructure-level dosimetry revealed substantial absorbed dose heterogeneity for both radiopharmaceuticals, which is not considered with simplistic whole-organ dosimetry. Small-scale dosimetry enables identification of possible dose-limiting nephron substructures, informing future nephroprotective strategies and improving the translational evaluation of novel radioligands.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Andersson M, Opsomer T, Saldarriaga Vargas C, et al. Nephron-Level Dosimetry Reveals Increased Absorbed Dose Heterogeneity of 161Tb- Versus 177Lu-DOTATATE in Murine Kidneys Despite Similar Pharmacokinetics. J Nucl Med. 2026. PMID: 42167802. doi:10.2967/jnumed.125.271864

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。